insights_auto
Why is LSTA down 11.67%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
$1.06
arrow_downward
-11.67%(-0.14) 1D
Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
$1.28
High
$1.28
Low
$1.02
Mkt. cap
11.45M
Avg. vol.
252.24K
Volume
280.16K
52-wk high
$5.06
52-wk low
$0.99
EPS
-$1.64
Beta
0.94
Shares outstanding
9.01M
No. of employees
21
Open
$1.28
High
$1.28
Low
$1.02
Mkt. cap
11.45M
Avg. vol.
252.24K
Volume
280.16K
52-wk high
$5.06
52-wk low
$0.99
EPS
-$1.64
Beta
0.94
Shares outstanding
9.01M
No. of employees
21
News stories
From web sources and news partners
Investing.com
·
1 day ago
Lisata Therapeutics receives patent for certepetide cancer treatment
Stock Titan
·
1 day ago
A new cancer-treatment patent adds market exclusivity into 2043, Lisata says.
Investing.com UK
·
1 day ago
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com
www.dars.gov.et
·
2 months ago
LSTA Q3 2025 Earnings: Narrower-than-Expected Loss as Clinical Progress Continues - Return On Equity
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorBiotechnology
Websitelisata.com